Clinical Trial Update: A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/ Phase 2 biomarker trial evaluating UAB30 in renal transplant recipients at high risk for non-melanoma skin cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-melanoma Skin Cancer

Drugs mentioned

• UAB30

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Non-melanoma Skin Cancer | Phase 1, Phase 2 | Status: WITHDRAWN